Every 10-Q that Firefly Neuroscience, Inc. (AIFF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIFF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIFF filings page.
Firefly Neuroscience, Inc. reported continued operating losses for the quarter and six months ended June 30, 2026 while significantly expanding its balance sheet through equity financings. Revenue reached $514 thousand for the quarter and $999 thousand for the first half of 2026, up sharply from 2025 levels, largely driven by the Evoke Neuroscience acquisition and subscription-based deployments of its FDA-cleared Evoke EEG System across more than 85 U.S. sites.
Total assets rose to $16.8 million, with cash and cash equivalents increasing to $9.2 million from $2.7 million at year-end 2025, primarily due to March–April 2026 private placements that generated about $10.3 million in net proceeds. Shareholders’ equity improved to $14.7 million, although the company still carried an accumulated deficit of $115.6 million and an operating cash outflow of $3.7 million in the first half.
Management explicitly states that recurring losses, negative operating cash flows, and insufficient revenue raise substantial doubt about the ability to continue as a going concern within one year. An at-the-market facility of up to $7.4 million remains unused, and 14.6 million warrants plus equity awards represent significant potential dilution. Management also concludes that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 due to material weaknesses, with remediation efforts ongoing.
Firefly Neuroscience, Inc. reported significantly higher quarterly revenue but continued losses and liquidity pressure. For the three months ended March 31, 2026, revenue rose to $485 thousand from $43 thousand, mainly from the Evoke Neuroscience acquisition, while net loss narrowed to $2.0 million from $12.9 million. Operating expenses were $2.2 million, similar to the prior year, and cash used in operations was $1.95 million.
The company ended the quarter with $3.1 million in cash and an accumulated deficit of $113.6 million, and its auditors and management stated that these conditions raise substantial doubt about its ability to continue as a going concern. To bolster liquidity, Firefly raised $2.4 million in Q1 2026 and a further $8.0 million in April through unit private placements, and it put in place a $7.4 million at-the-market stock offering and a pending up to $1.0 million units offering, all of which depend on market access.
Firefly Neuroscience (AIFF) reported Q3 2025 results. Revenue rose to $388 thousand, driven mainly by the Evoke acquisition, yielding gross profit of $146 thousand. Operating loss was $2.656 million and net loss was $2.639 million for the quarter. For the nine months, revenue reached $730 thousand and net loss was $17.402 million, including a $9.369 million loss from change in derivative fair value and a $1.353 million loss on settlement of a convertible note.
Cash was $4.325 million at September 30, 2025; net cash used in operating activities was $6.389 million for the nine months. The company completed the Evoke Neuroscience deal for $3.0 million in cash plus 857,142 shares (valued at $2.743 million) and contingent consideration of $478 thousand, recording $5.175 million of goodwill. Management disclosed that recurring losses and limited revenue raise “substantial doubt” about continuing as a going concern. Common shares outstanding were 13,482,511 as of November 6, 2025.